These are top 10 stocks traded on the Robinhood UK platform in July
On Thursday, Barclays (LON:BARC) analyst team made a significant adjustment to ICON plc's (NASDAQ:ICLR) stock rating, downgrading it from Overweight to Equalweight. Accompanying this downgrade was a substantial reduction in the price target, now set at $165, a decrease from the previous target of $240. The stock, which has declined nearly 48% over the past six months, appears undervalued according to InvestingPro Fair Value analysis, despite trading at an attractive P/E ratio of 16.15.
The Barclays analysts pointed out that removing the Biomedical Advanced Research and Development Authority (BARDA) contracts from consideration would place ICON's new revenue guidance at the lower end of the original forecast. Despite this, earnings per share (EPS) guidance remains above the lower threshold. The analysts considered this a positive aspect, suggesting it provides a solid base for the company's financial outlook. InvestingPro data reveals strong fundamentals, with a healthy free cash flow yield and management actively buying back shares, suggesting confidence in the company's future.
The review by Barclays also noted potential challenges for ICON. The expected bookings for the first quarter are anticipated to be subdued, as indicated by recent conference discussions. ICON is facing unique headwinds, particularly due to its higher customer concentration among top clients and the impact of the BARDA vaccine contracts. While the company's competitor IQVIA is also subject to similar market dynamics, ICON is perceived to have a higher level of exposure to these challenges.
Despite the downgrade, Barclays still holds a favorable view of ICON in the longer term, spanning a 2-3 year period. This optimism is partly based on ICON's strong balance sheet and the management's transparency, which Barclays believes will enable accurate predictions of the company's future performance. Nevertheless, the analysts expressed caution, suggesting that it may be premature for investors to engage with ICON's stock at this juncture. For a deeper understanding of ICON's potential, investors can access comprehensive valuation metrics, financial health scores, and additional ProTips through InvestingPro's detailed research report, part of its coverage of over 1,400 US stocks.
In other recent news, ICON plc reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with earnings per share (EPS) of $3.43 and revenue of $2.04 billion, slightly above the forecasted figures. Despite a 1.2% year-over-year decrease in quarterly revenue, the company saw a 2% increase in full-year revenue. Meanwhile, Goldman Sachs downgraded ICON's stock from Buy to Neutral and reduced the price target to $200, citing inconsistent recent performance and a weaker demand environment. Truist Securities maintained its Buy rating with a $262 price target, notwithstanding a 90-day delay in a significant COVID vaccine study managed by ICON. Evercore ISI also reiterated its Outperform rating with a $225 price target, acknowledging the study delay but expressing confidence in ICON's long-term outlook. Leerink Partners adjusted its price target to $235 from $243 while maintaining an Outperform rating, noting challenges due to the vaccine trial delay but remaining optimistic about ICON's future. Despite these setbacks, ICON has reaffirmed its full-year 2025 guidance, indicating its resilience and strategic focus on digital innovation and automation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.